ALX Oncology Appoints Allison Dillon as Chief Business Officer
Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block ...
Medscape27d
How Zelboraf (Vemurafenib), a New FDA-Approved Therapy, Extends Life for Patients With Metastatic Melanoma
That all changed over the past year with the approval of Yervoy™ and Zelboraf™. In this issue of The Melanoma Letter, Dr. Paul Chapman discusses the exciting, newly FDA-approved drug Zelboraf ...
Stockhouse10d
ALX Oncology Appoints Allison Dillon as Chief Business Officer
She served in marketing and sales roles for AVASTIN® (bevacizumab), TARCEVA® (erlotinib), ZELBORAF® (vemurafenib), and TECENTRIQ. Prior to Genentech, Dr. Dillon was a Senior ...
Morningstar10d
ALX Oncology Appoints Allison Dillon as Chief Business Officer
She served in marketing and sales roles for AVASTIN® (bevacizumab), TARCEVA® (erlotinib), ZELBORAF® (vemurafenib), and TECENTRIQ. Prior to Genentech, Dr. Dillon was a Senior Consultant at the ...
Business Insider10d
ALX Oncology Appoints Allison Dillon as Chief Business Officer
She served in marketing and sales roles for AVASTIN® (bevacizumab), TARCEVA® (erlotinib), ZELBORAF® (vemurafenib), and TECENTRIQ. Prior to Genentech, Dr. Dillon was a Senior Consultant at the ...
Finanznachrichten10d
ALX Oncology Appoints Allison Dillon as Chief Business Officer
She served in marketing and sales roles for AVASTIN® (bevacizumab), TARCEVA® (erlotinib), ZELBORAF® (vemurafenib), and TECENTRIQ. Prior to Genentech, Dr. Dillon was a Senior Consultant at the ...
BioSpace11d
ALX Oncology Appoints Allison Dillon as Chief Business Officer
She served in marketing and sales roles for AVASTIN® (bevacizumab), TARCEVA® (erlotinib), ZELBORAF® (vemurafenib), and TECENTRIQ. Prior to Genentech, Dr. Dillon was a Senior Consultant at the ...
Medscape29d
Drug Discovery in Ophthalmology
Understanding why the drug development programme targeting VEGF was so successful compared to many notable failures in the industry is difficult. The drugs were the product of decades of research ...
ahajournals.org29d
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase
Cardiovascular Research Center (L.X., S.C., A.H., A.B., J.T., M.N., P.T.E., D.J.M.), Massachusetts General Hospital and Harvard Medical School, Boston, MA. Clinical ...
biopharma-reporter3d
Markets & Regulations
Daniel Spurgin, director of strategic partnerships at ReciBioPharm, unveiled the company's BIO 2024 plans and how the CDMO is set to flourish as more viral and nucleic acid therapeutics move to the ...
biopharma-reporter22d
Hot Topics
In a recent interview, Hayley Crowe, head of Ecolab's global life sciences business, shed light on Purolite's latest developments and its significant contributions to the biopharmaceutical industry.